Our Approach

Cancer results from mutations that fundamentally alter the properties of normal cells and allow tumors to form, grow, metastasize, and evade treatment.

We aim to improve outcomes for cancer patients by leveraging a deep understanding of tumor biology and cancer pharmacology to identify and advance underdeveloped drug candidates.

We Study the Fundamental Biological Differences Between Normal and Cancer Cells

Underdeveloped drug candidates include approved or development-stage therapies that can be used in new ways or whose development was stopped due to a lack of a clear understanding of the drug’s anticancer mechanism or a lack of capital to support advancement and commercialization.

By studying the fundamental biological differences between normal and cancer cells in conjunction with how current therapies act against them, we seek to identify and acquire select underdeveloped drug candidates and specifically target them to patients whose tumors are most likely to respond to treatment.

Wherever possible, we seek to license or acquire rights to late-preclinical or clinical stage drug candidates where we can leverage existing safety and efficacy under FD&C Sec. 505(b)(2). In addition, we seek to concentrate on product opportunities that we believe are likely to be eligible for accelerated marketing approval under the USFDA’s expedited approval program for serious conditions (21 CFR part 314, subpart H).

We believe that this approach may not only decrease the overall cost, regulatory and technical risk of drug development, but also reduce the time required to to obtain FDA approval and get important new treatments to patients.